Pacifichealth Laboratories Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2012. Revenues were $1,721,119 for the third quarter ended September 30, 2012 compared to $1,971,624 for the same period in 2011. The company said that the biggest impact to revenue in the third quarter was the transitioning from its old formula ACCELERADE and ENDUROX R4 to its new all-natural formulas. Net loss for the third quarter of 2012 was $345,439, or $0.02 per share, compared to a net loss of $116,675, or $0.01 per share for the third quarter of 2011. Loss before other expense and provision for income taxes was $337,880 against $109,420 a year ago. Loss before provision for income taxes was $345,439 against $116,675 a year ago.

For the nine months, the company's revenues were $5,701,292 compared to $5,948,461 for the same period in 2011. Net loss for the nine months of 2012 was $454,965, or $0.02 per share, compared to a net income of $2,324, or $0.00 per diluted share, for the nine months ended September 30, 2011. Loss before other expense and provision for income taxes was $439,014 against income of $13,603 a year ago. Loss before provision for income taxes was $454,965 against income of $2,324 a year ago.